# Transact Technologies Inc: financial statements, quarterly

TACT · Nasdaq · CIK 1017303 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tact.md) · [Financials](/companies/tact/financials.md) · [Filings](/companies/tact/filings.md) · [Insiders](/companies/tact/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tact/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.2](/filings/0001140361-25-010065.md) | [13.3](/filings/0001140361-25-010065.md) | [10.7](/filings/0001140361-26-009238.md) | [11.6](/filings/0001140361-26-009238.md) | [10.9](/filings/0001140361-26-009238.md) | [10.2](/filings/0001140361-26-009238.md) | [13.1](/filings/0001140361-26-021058.md) | [13.8](/filings/0001140361-26-033093.md) | [13.2](/filings/0001140361-26-009238.md) | [11.5](/filings/0001140361-26-009238.md) | [14.4](/filings/0001140361-26-021058.md) | [13.9](/filings/0001140361-26-033093.md) |
| Cost of revenue | $m | [8.3](/filings/0001140361-24-046203.md) | [6.9 d](/filings/0001140361-25-010065.md) | [5.1](/filings/0001140361-25-018987.md) | [5.5](/filings/0001140361-25-030285.md) | [5.6](/filings/0001140361-25-041994.md) | [5.7 d](/filings/0001140361-26-009238.md) | [6.7](/filings/0001140361-26-021058.md) | [7.1](/filings/0001140361-26-033093.md) | [6.6](/filings/0001140361-25-041994.md) | [6.0 d](/filings/0001140361-26-009238.md) | [7.2](/filings/0001140361-26-021058.md) | [6.9](/filings/0001140361-26-033093.md) |
| Gross profit | $m | [8.9](/filings/0001140361-25-010065.md) | [6.4](/filings/0001140361-25-010065.md) | [5.6](/filings/0001140361-26-009238.md) | [6.1](/filings/0001140361-26-009238.md) | [5.2](/filings/0001140361-26-009238.md) | [4.5](/filings/0001140361-26-009238.md) | [6.4](/filings/0001140361-26-021058.md) | [6.7](/filings/0001140361-26-033093.md) | [6.6](/filings/0001140361-26-009238.md) | [5.4](/filings/0001140361-26-009238.md) | [7.3](/filings/0001140361-26-021058.md) | [7.0](/filings/0001140361-26-033093.md) |
| Research and development | $m | [2.5](/filings/0001140361-24-046203.md) | [2.2 d](/filings/0001140361-25-010065.md) | [2.0](/filings/0001140361-25-018987.md) | [1.8](/filings/0001140361-25-030285.md) | [1.6](/filings/0001140361-25-041994.md) | [1.6 d](/filings/0001140361-26-009238.md) | [1.6](/filings/0001140361-26-021058.md) | [1.7](/filings/0001140361-26-033093.md) | [1.7](/filings/0001140361-25-041994.md) | [1.7 d](/filings/0001140361-26-009238.md) | [1.4](/filings/0001140361-26-021058.md) | [1.2](/filings/0001140361-26-033093.md) |
| Operating income | $m | [1.2](/filings/0001140361-24-046203.md) | [(0.5) d](/filings/0001140361-25-010065.md) | [(1.3)](/filings/0001140361-25-018987.md) | [(0.4)](/filings/0001140361-25-030285.md) | [(0.8)](/filings/0001140361-25-041994.md) | [(1.1) d](/filings/0001140361-26-009238.md) | [(0.0)](/filings/0001140361-26-021058.md) | [(0.3)](/filings/0001140361-26-033093.md) | [0.0](/filings/0001140361-25-041994.md) | [(1.2) d](/filings/0001140361-26-009238.md) | [0.8](/filings/0001140361-26-021058.md) | [(0.1)](/filings/0001140361-26-033093.md) |
| Income tax | $m | [0.2](/filings/0001140361-24-046203.md) | [(0.0) d](/filings/0001140361-25-010065.md) | [(0.3)](/filings/0001140361-25-018987.md) | [(0.1)](/filings/0001140361-25-030285.md) | [(0.1)](/filings/0001140361-25-041994.md) | [6.8 d](/filings/0001140361-26-009238.md) | [0.1](/filings/0001140361-26-021058.md) | [0.0](/filings/0001140361-26-033093.md) | [0.0](/filings/0001140361-25-041994.md) | [0.0 d](/filings/0001140361-26-009238.md) | [0.0](/filings/0001140361-26-021058.md) | [0.0](/filings/0001140361-26-033093.md) |
| Net income | $m | [0.9](/filings/0001140361-25-010065.md) | [(0.1)](/filings/0001140361-25-010065.md) | [(1.0)](/filings/0001140361-26-009238.md) | [(0.3)](/filings/0001140361-26-009238.md) | [(0.6)](/filings/0001140361-26-009238.md) | [(8.0)](/filings/0001140361-26-009238.md) | [0.0](/filings/0001140361-26-021058.md) | [(0.1)](/filings/0001140361-26-033093.md) | [0.0](/filings/0001140361-26-009238.md) | [(1.1)](/filings/0001140361-26-009238.md) | [0.8](/filings/0001140361-26-021058.md) | [(0.1)](/filings/0001140361-26-033093.md) |
| Diluted EPS | $ per share | [0.09](/filings/0001140361-25-010065.md) | [(0.01)](/filings/0001140361-25-010065.md) | [(0.10)](/filings/0001140361-26-009238.md) | [(0.03)](/filings/0001140361-26-009238.md) | [(0.06)](/filings/0001140361-26-009238.md) | [(0.79)](/filings/0001140361-26-009238.md) | [0.00](/filings/0001140361-26-021058.md) | [(0.01)](/filings/0001140361-26-033093.md) | [0.00](/filings/0001140361-26-009238.md) | [(0.11)](/filings/0001140361-26-009238.md) | [0.07](/filings/0001140361-26-021058.md) | [0.00](/filings/0001140361-26-033093.md) |
| Basic EPS | $ per share | [0.09](/filings/0001140361-25-010065.md) | [(0.01)](/filings/0001140361-25-010065.md) | [(0.10)](/filings/0001140361-26-009238.md) | [(0.03)](/filings/0001140361-26-009238.md) | [(0.06)](/filings/0001140361-26-009238.md) | [(0.79)](/filings/0001140361-26-009238.md) | [0.00](/filings/0001140361-26-021058.md) | [(0.01)](/filings/0001140361-26-033093.md) | [0.00](/filings/0001140361-26-009238.md) | [(0.11)](/filings/0001140361-26-009238.md) | [0.08](/filings/0001140361-26-021058.md) | [0.00](/filings/0001140361-26-033093.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.6](/filings/0001140361-23-053150.md) | [12.3](/filings/0001140361-25-010065.md) | [10.6](/filings/0001140361-24-026005.md) | [11.1](/filings/0001140361-24-036631.md) | [11.3](/filings/0001140361-24-046203.md) | [14.4](/filings/0001140361-26-009238.md) | [14.2](/filings/0001140361-25-018987.md) | [17.7](/filings/0001140361-25-030285.md) | [20.0](/filings/0001140361-25-041994.md) | [20.4](/filings/0001140361-26-033093.md) | [18.8](/filings/0001140361-26-021058.md) | [19.4](/filings/0001140361-26-033093.md) |
| Current assets | $m | [42.7](/filings/0001140361-23-053150.md) | [41.0](/filings/0001140361-25-010065.md) | [38.9](/filings/0001140361-24-026005.md) | [37.0](/filings/0001140361-24-036631.md) | [37.4](/filings/0001140361-24-046203.md) | [38.4](/filings/0001140361-26-009238.md) | [38.9](/filings/0001140361-25-018987.md) | [39.7](/filings/0001140361-25-030285.md) | [39.2](/filings/0001140361-25-041994.md) | [38.8](/filings/0001140361-26-033093.md) | [38.7](/filings/0001140361-26-021058.md) | [40.6](/filings/0001140361-26-033093.md) |
| Total assets | $m | [56.7](/filings/0001140361-23-053150.md) | [54.2](/filings/0001140361-25-010065.md) | [51.9](/filings/0001140361-24-026005.md) | [50.4](/filings/0001140361-24-036631.md) | [50.5](/filings/0001140361-24-046203.md) | [44.0](/filings/0001140361-26-009238.md) | [44.2](/filings/0001140361-25-018987.md) | [44.5](/filings/0001140361-25-030285.md) | [45.0](/filings/0001140361-25-041994.md) | [44.8](/filings/0001140361-26-033093.md) | [47.9](/filings/0001140361-26-021058.md) | [51.0](/filings/0001140361-26-033093.md) |
| Current liabilities | $m | [16.1](/filings/0001140361-23-053150.md) | [13.6](/filings/0001140361-25-010065.md) | [12.5](/filings/0001140361-24-026005.md) | [10.7](/filings/0001140361-24-036631.md) | [11.3](/filings/0001140361-24-046203.md) | [12.9](/filings/0001140361-26-009238.md) | [12.8](/filings/0001140361-25-018987.md) | [12.9](/filings/0001140361-25-030285.md) | [12.8](/filings/0001140361-25-041994.md) | [13.0](/filings/0001140361-26-033093.md) | [12.4](/filings/0001140361-26-021058.md) | [15.3](/filings/0001140361-26-033093.md) |
| Total liabilities | $m | [17.5](/filings/0001140361-23-053150.md) | [14.8](/filings/0001140361-25-010065.md) | [13.3](/filings/0001140361-24-026005.md) | [11.8](/filings/0001140361-24-036631.md) | [12.1](/filings/0001140361-24-046203.md) | [13.4](/filings/0001140361-26-009238.md) | [13.2](/filings/0001140361-25-018987.md) | [13.3](/filings/0001140361-25-030285.md) | [13.2](/filings/0001140361-25-041994.md) | [13.7](/filings/0001140361-26-033093.md) | [15.6](/filings/0001140361-26-021058.md) | [18.3](/filings/0001140361-26-033093.md) |
| Shareholders' equity | $m | [39.2](/filings/0001140361-24-046203.md) | [39.4](/filings/0001140361-26-009238.md) | [38.6](/filings/0001140361-25-030285.md) | [38.5](/filings/0001140361-25-041994.md) | [38.4](/filings/0001140361-25-041994.md) | [30.6](/filings/0001140361-26-033093.md) | [30.9](/filings/0001140361-26-033093.md) | [31.3](/filings/0001140361-26-033093.md) | [31.8](/filings/0001140361-25-041994.md) | [31.1](/filings/0001140361-26-033093.md) | [32.3](/filings/0001140361-26-033093.md) | [32.7](/filings/0001140361-26-033093.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [901 d](/filings/0001140361-24-046203.md) | [916 d](/filings/0001140361-25-010065.md) | [(1,490)](/filings/0001140361-25-018987.md) | [636 d](/filings/0001140361-25-030285.md) | [327 d](/filings/0001140361-25-041994.md) | [2,388 d](/filings/0001140361-26-009238.md) | [(161)](/filings/0001140361-26-021058.md) | [3,595 d](/filings/0001140361-26-033093.md) | [3,630 d](/filings/0001140361-25-041994.md) | [609 d](/filings/0001140361-26-009238.md) | [(946)](/filings/0001140361-26-021058.md) | [2,155 d](/filings/0001140361-26-033093.md) |
| Capital expenditure | $k | [99.0 d](/filings/0001140361-24-046203.md) | [113 d](/filings/0001140361-25-010065.md) | [106](/filings/0001140361-25-018987.md) | [137 d](/filings/0001140361-25-030285.md) | [68.0 d](/filings/0001140361-25-041994.md) | [11.0 d](/filings/0001140361-26-009238.md) | [10.0](/filings/0001140361-26-021058.md) | [19.0 d](/filings/0001140361-26-033093.md) | [60.0 d](/filings/0001140361-25-041994.md) | [20.0 d](/filings/0001140361-26-009238.md) | [80.0](/filings/0001140361-26-021058.md) | [57.0 d](/filings/0001140361-26-033093.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.9](/filings/0001140361-23-053150.md) | [10.0](/filings/0001140361-24-026005.md) | [10.0](/filings/0001140361-24-036631.md) | [10.1](/filings/0001140361-24-046203.md) | [10.0](/filings/0001140361-25-018987.md) | [10.0](/filings/0001140361-25-030285.md) | [10.0](/filings/0001140361-25-041994.md) | [10.1](/filings/0001140361-26-021058.md) | [10.1](/filings/0001140361-26-033093.md) | [10.2](/filings/0001140361-25-041994.md) | [10.2](/filings/0001140361-26-021058.md) | [10.3](/filings/0001140361-26-033093.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,324,471 at 2026-07-31, from the cover of the [10-Q filed 2026-08-14](/filings/0001140361-26-033093.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.